Article

Gut Microbiome Diversity and Specific Composition During Immunotherapy in Japanese Responders with Non-Small Cell Lung Cancer

2021-06-28

Abstract excerpt

<title>Abstract</title> <p>Cancer immunotherapy including immune checkpoint inhibitors (ICI) has revolutionized non-small cell lung cancer (NSCLC) therapy. Recently, the microbiome status before initiation of ICI therapy has been emphasized as a predictive biomarker in patients undergoing ICI therapy. However, the microbiome diversity and composition during ICI therapy is unknown. This multicenter, prospective ob...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: d9b5ca11-a446-5960-8858-6b963b55116a
DOI: 10.21203/rs.3.rs-633455/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Gut Microbiome Diversity and Specific Composition During Immunotherapy in Japanese Responders with Non-Small Cell Lung CancerDOI 10.21203/rs.3.rs-633455/v1Read

Gut microbiota diversity and specific composition during immunotherapy in responders with non-small cell lung cancerSemantic proximity Read

Gut Microbiota a Novel Source of Biomarkers for Immunotherapy in Non-small Cell Lung Cancer (NSCLC)Semantic proximity Read

Characteristics of Microbiome in Lung Adenocarcinoma Tissue from Patients in Southwestern ChinaSemantic proximity Read

Understanding Microbiome Effect on Immune Checkpoint Inhibition in Lung Cancer: Placing the Puzzle Pieces TogetherSemantic proximity Read

Distinct Functional Metagenomic Markers Predict the Responsiveness to Anti-PD-1 Therapy in Chinese Non-Small Cell Lung Cancer PatientsSemantic proximity Read

Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung CancerSemantic proximity Read

Response to PD-1-Based Immunotherapy for Non-Small Cell Lung Cancer Altered by Gut MicrobiotaSemantic proximity Read

Gut Metatranscriptomics Based De Novo Assembly Reveals Microbial Signatures Predicting Immunotherapy outcomes in Non-Small Cell Lung CancerSemantic proximity Read

Gut microbiome metabolites, molecular mimicry, and species-level variation drive long-term efficacy and adverse event outcomes in lung cancer survivorsSemantic proximity Read

Distinct gut virome profiles are associated with response to anti-PD-1 therapy in non-small cell lung cancerSemantic proximity Read

The Gut Microbiome as a Promising Biomarker of Cancer Progression Among Female Never-smokers With Lung AdenocarcinomaSemantic proximity Read

Metagenomic and Metabolomic Correlates of Immunotherapy Response in Non-Small Cell Lung CancerSemantic proximity Read